October is here and it's make it or break it for many small biotech companies. I am looking at AVNR, BIOD, and ALXA at the moment.

AVNR has good chance of approval while ALXA and BIOD are in doubts. Personally I think BIOD will be reject considering they ignore to correct the anomalies...